Literature DB >> 12698048

Collaborative normal tension glaucoma study.

Douglas R Anderson1.   

Abstract

PURPOSE OF REVIEW: Before this study was done, there was a difference of opinion concerning whether intraocular pressure (IOP) was involved in producing optic nerve damage when there was glaucomatous damage to the optic nerve and characteristic visual field loss, even though the IOP was in the statistically normal range. This article reviews the findings of a collaborative study aimed at finding the answer to this question. RECENT
FINDINGS: The level of pressure influences the course of normal tension glaucoma, as evidenced by a slower rate of incident visual field loss in cases with 30% or more lowering of intraocular pressure. The rate of progression without treatment is highly variable, but often slow enough that half of the patients have no progression in 5 years. A faster rate occurs in women, in patients with migraine headaches, and in the presence of disc hemorrhages. Some patients may experience greater benefit from lowering of IOP than others, but further research is needed to be able to identify those most likely to benefit.
SUMMARY: As a group, patients with normal tension glaucoma benefit from lowering of IOP. Variable rate of deterioration, as well as lack of progression in a substantial number in 5 years, suggest that treatment should be individualized according to the stage of disease and rate of progression. Traits that help predict risk and rate of progression and response to treatment are beginning to become known and, when fully known, will help guide management decisions.

Entities:  

Mesh:

Year:  2003        PMID: 12698048     DOI: 10.1097/00055735-200304000-00006

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  94 in total

Review 1.  Cellular and molecular biology of optineurin.

Authors:  Hongyu Ying; Beatrice Y J T Yue
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

2.  Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action.

Authors:  Grace C Shih; David J Calkins
Journal:  Expert Rev Ophthalmol       Date:  2012-04

3.  [Optic neuropathy in Schmidt-Carpenter syndrome].

Authors:  P C Horn; J Harder; C P Lohmann; I Lanzl
Journal:  Ophthalmologe       Date:  2010-07       Impact factor: 1.059

4.  [Position statement of the German Ophthalmological Society on early recognition of glaucoma : August 2015].

Authors: 
Journal:  Ophthalmologe       Date:  2016-01       Impact factor: 1.059

5.  Prioritizing outcome preferences in patients with ocular hypertension and open-angle glaucoma using best-worst scaling.

Authors:  Jimmy T Le; Amanda K Bicket; Ellen M Janssen; Davinder Grover; Sunita Radhakrishnan; Steven Vold; Michelle E Tarver; Malvina Eydelman; John F P Bridges; Tianjing Li
Journal:  Ophthalmol Glaucoma       Date:  2019-09-03

6.  [Functional morphology of the outflow pathways of aqueous humor and their changes in open angle glaucoma].

Authors:  E R Tamm
Journal:  Ophthalmologe       Date:  2013-11       Impact factor: 1.059

7.  Long-Term Follow-Up of Normal Tension Glaucoma Patients With TBK1 Gene Mutations in One Large Pedigree.

Authors:  Tyler S Quist; Chris A Johnson; Alan L Robin; John H Fingert
Journal:  Am J Ophthalmol       Date:  2020-01-24       Impact factor: 5.258

8.  The effects of graded intraocular pressure challenge on the optic nerve head.

Authors:  Nimesh Patel; Faith McAllister; Laura Pardon; Ronald Harwerth
Journal:  Exp Eye Res       Date:  2018-02-01       Impact factor: 3.467

9.  Aqueous humor phospholipids of DBA/2J and DBA/2J-Gpnmb(+)/SjJ mice.

Authors:  Haiyan Wang; Genea Edwards; Catalina Garzon; Carmen Piqueras; Sanjoy K Bhattacharya
Journal:  Biochimie       Date:  2015-04-02       Impact factor: 4.079

Review 10.  Prospects for lentiviral vector mediated prostaglandin F synthase gene delivery in monkey eyes in vivo.

Authors:  Eun Suk Lee; Carol A Rasmussen; Mark S Filla; Sarah R Slauson; Aaron W Kolb; Donna M Peters; Paul L Kaufman; B'Ann T Gabelt; Curtis R Brandt
Journal:  Curr Eye Res       Date:  2014-02-21       Impact factor: 2.424

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.